Ipratropium bromide

This product is a compound preparation, its components are: salbutamol sulfate 24mg and ipratropium bromide 4mg.

No adverse reactions have been reported with the combination of ipratropium with some of the drugs commonly used in the treatment of COPD, such as sympathomimetic bronchodilators, methylxanthines, and steroids. No formal drug interaction studies have been conducted with ipratropium with drugs commonly used in the treatment of COPD. Anticholinergics: Although ipratropium is absorbed into the systemic circulation in very small amounts, additional interactions may occur with anticholinergic drugs. Therefore, this product should be used with caution with other anticholinergic drugs. Beta-adrenergics: Due to the increased risk of adverse cardiovascular reactions, this product should be used with caution with other sympathomimetics. Beta-blockers: These drugs interact with salbutamol to inhibit the effects of salbutamol. Beta-blockers should be used with caution in patients with hyperreactive airways. Diuretics: Beta-agonists, especially when taken at doses exceeding the recommended dose, can rapidly worsen electrocardiographic changes and/or hypokalemia induced by potassium-sparing diuretics (e.g., loop or thiazide diuretics). Although the clinical significance of this phenomenon is unclear, caution should be exercised when using drugs containing beta-agonists in combination with potassium-sparing drugs. Monoamine oxidase inhibitors or tricyclic antidepressants: Since salbutamol may enhance the effects on the cardiovascular system, patients who are taking monoamine oxidase inhibitors or tricyclic antidepressants or who have stopped taking such drugs within 2 weeks should be extremely cautious when using this product.

The main ingredients of this product and their chemical names: This product is a compound preparation, and its components are as follows: Each vial (2.5 ml) of inhalation solution contains: (8γ)-3α-hydroxy-8-isopropyl-1αH,5αH-bromotropium (±)-tropate monohydrate (= ipratropium bromide monohydrate) 0.52 mg, equivalent to 0.500 mg of ipratropium bromide; (RS)-2-tert-butylamino-1-[4-hydroxy]-3-(hydroxymethyl)phenyl]-ethanol sulfate (= salbutamol sulfate) 3.000 mg, equivalent to 2.5 mg of salbutamol base

Concomitant use of xanthine derivatives, beta-adrenergics and anticholinergics may increase side effects. Xanthine derivatives, corticosteroids and diuretics may enhance hypokalemia caused by beta-agonists. Special attention should be paid to patients with severe airway obstruction. Hypokalemia may increase the risk of arrhythmias in patients taking digoxin. It is recommended to monitor blood potassium levels in this case. Concomitant use of beta-blockers may significantly reduce the effect of bronchodilators. Beta-adrenergic agonists should be used with caution in patients who are receiving monoamine oxidase inhibitors or tricyclic antidepressants, as the effects of beta-adrenergic agonists may be enhanced. Inhaled halogenated hydroxy anesthetics such as halothane, trichloroethylene and enflurane